These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25949896)

  • 1. Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells.
    Mamidi S; Höne S; Teufel C; Sellner L; Zenz T; Kirschfink M
    Oncoimmunology; 2015 Mar; 4(3):e979688. PubMed ID: 25949896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
    Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
    J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
    Mamidi S; Cinci M; Hasmann M; Fehring V; Kirschfink M
    Mol Oncol; 2013 Jun; 7(3):580-94. PubMed ID: 23474221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
    Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
    Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
    Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
    J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.
    Baig NA; Taylor RP; Lindorfer MA; Church AK; Laplant BR; Pavey ES; Nowakowski GS; Zent CS
    Leuk Lymphoma; 2012 Nov; 53(11):2218-27. PubMed ID: 22475085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
    Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
    Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity.
    Hörl S; Bánki Z; Huber G; Ejaz A; Windisch D; Muellauer B; Willenbacher E; Steurer M; Stoiber H
    Leukemia; 2013 Nov; 27(11):2200-8. PubMed ID: 23760402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.
    Bologna L; Gotti E; Da Roit F; Intermesoli T; Rambaldi A; Introna M; Golay J
    J Immunol; 2013 Jan; 190(1):231-9. PubMed ID: 23225880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.
    Loeff FC; van Egmond HME; Nijmeijer BA; Falkenburg JHF; Halkes CJ; Jedema I
    Leuk Lymphoma; 2017 Sep; 58(9):1-14. PubMed ID: 28140725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
    Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
    Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.
    Cinci M; Mamidi S; Li W; Fehring V; Kirschfink M
    Target Oncol; 2015 Sep; 10(3):405-13. PubMed ID: 25395366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.
    Zell S; Geis N; Rutz R; Schultz S; Giese T; Kirschfink M
    Clin Exp Immunol; 2007 Dec; 150(3):576-84. PubMed ID: 17903221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
    Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH
    Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
    Lara S; Heilig J; Virtanen A; Kleinau S
    BMC Cancer; 2022 Jun; 22(1):678. PubMed ID: 35725455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
    Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
    Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
    Harjunpää A; Junnikkala S; Meri S
    Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL.
    Middleton O; Cosimo E; Dobbin E; McCaig AM; Clarke C; Brant AM; Leach MT; Michie AM; Wheadon H
    Leukemia; 2015 Jan; 29(1):107-14. PubMed ID: 24787488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.